Lifirafenib Drug Asset Due Diligence Report 2026

This Lifirafenib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Lifirafenib can convert its Small molecule drug profile and ARAF x BRAF V600E x CRAF biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Lifirafenib (query alias: Lifirafenib)
Modality / target	Small molecule drug; ARAF x BRAF V600E x CRAF; ARAF inhibitors, BRAF V600E inhibitors, CRAF inhibitors
Highest global status	Phase 2
Originator	BeOne Medicines Ltd.
Active developers	BeOne Medicines Ltd.

The MCP disease footprint includes Colorectal Cancer, Non-Small Cell Lung Cancer, Central Nervous System Neoplasms. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT03905148	Phase 1	Completed	91	Primary endpoint not disclosed in English source
NCT03641586	Phase 1	Completed	42	Primary endpoint not disclosed in English source
NCT02610361	Phase 1	Completed	131	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Abstract CT033: Safety, pharmacokinetics, and antitumor activity findings from a phase 1b, open-label, dose-escalation and expansion study investigating RAF dimer inhibitor lifirafenib in combination with MEK inhibitor mirdametinib in patients with advanced or refractory solid tumors

Phase 1; n=56; evaluation: Positive. Reported fields: DCR = 72.2 % ; DCR = 94.1 %

Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors

Phase 1; n=not disclosed; evaluation: Positive. Reported fields: DLT = dose-limiting toxicities included reversible thrombocytopenia and nonhematologic toxicity.

Abstract CT002: A Phase IB study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors

Phase 1; n=96; evaluation: Positive. Reported fields: RR = 42.9 % (95%CI, 9.9 - 81.6)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Lifirafenib addresses Colorectal Cancer, Non-Small Cell Lung Cancer, Central Nervous System Neoplasms. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 2 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2018-08-16	BeiGene and SpringWorks Therapeutics Enter into Global Clinical Collaboration to Evaluate Targeted Combination Therapy in Advanced Solid Tumors	Phase 2	Financial terms not disclosed
2013-05-31	Merck Enters Into Global Co-Development and Commercialization Agreement With Chinese R&D Company BeiGene on Second-Generation BRAF Inhibitor	Preclinical	US$232.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Application of small molecule compound in preparation of product for inhibiting 3C-like cysteine protease”. The milestone feed surfaced a patent-application signal described as “combinations”. The milestone feed surfaced a patent-application signal described as “Ribonucleotide reductase (RNR) compositions and methods of use”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO